Contributions
Abstract: EP1115
Type: E-Poster Presentation
Session title: Myeloproliferative neoplasms - Clinical
Background
The morbidity and mortality of BCR-ABL negative myeloproliferative neoplasms (polycythaemia vera, essential thrombocyhaemia and primary myelofibrosis) is highly dependent on thrombotic complications. In myeloproliferative neoplasia patients circulating platelets are already activated and they secrets higher levels of surface P-selectin and tissue factor. Anti-β2 glycoprotein 1 antibodies (β2GP1) bind to the β2GP1 receptors on the platelet surface, activating them that is important for thrombus formation. Antiphospholipid antibodies activates endothelial cells, whose dysfunction also plays an important role in the pathogenesis of thrombosis in BCR-ABL negative myeloproliferative neoplasia.
Aims
To evalute the antiphospholipid antibodies in relationship P Selectin Glycoprotein Ligand 1 (PSGL1) polymorphism on the development of thrombosis with other risk factors in patients with MPN.
Methods
A total of 105 MPN patients were included in this retrospective study. 58 of the MPN patients were diagnosed with essential thrombocythemia (ET), 41 with polycythemia vera (PV), 6 with myelofibrosis (MF). Clinical data about the development of thrombosis was collected. PSGL1 polymorphisms was determined from peripheral blood samples using PCR method. In electrophoresis the size of A allele was 558 bp, B allele – 528 bp. Data analysis was performed using “IBM SPSS Statistics 23”. There were two different selective and one confirmatory test for the LA determination. The detection of antibodies against β2-glycoprotein-1 (β2GP1) was performed using a chemiluminescent method. The detection of antibodies against cardiolipin (aCL) was performed by ELISA using commercial Aeskulisa Cardiolipin-GM (AESKU.DIAGNOSTICS, Germany).The interdependence of qualitative attributes was evaluated by the criterion of the chi square (χ2), and the Stjudent t-test or the Mann-Whitney U test was used to compare the quantitative characteristics. The data was statistically reliable when P<0.05.
Results
Arterial thrombotic complications were present in 38 (42.2%) of those with MPN. These patients were diagnosed with transient ischaemic attack (TIA), ischaemic stroke or myocardial infarction. aPL together with PSGL1 polymorphism were significant more frequently found in arterial thrombosis MPN patients compared with MPN patients who didn't experienced thrombosis (21.1% and 5.8%; p< 0.029).
Conclusion
Myeloproliferative neoplasm´s patients with antiphospholipid antibodies and PSGL1 polymorphism may have the increased risk of thrombosis development.
Keyword(s): Thrombosis
Abstract: EP1115
Type: E-Poster Presentation
Session title: Myeloproliferative neoplasms - Clinical
Background
The morbidity and mortality of BCR-ABL negative myeloproliferative neoplasms (polycythaemia vera, essential thrombocyhaemia and primary myelofibrosis) is highly dependent on thrombotic complications. In myeloproliferative neoplasia patients circulating platelets are already activated and they secrets higher levels of surface P-selectin and tissue factor. Anti-β2 glycoprotein 1 antibodies (β2GP1) bind to the β2GP1 receptors on the platelet surface, activating them that is important for thrombus formation. Antiphospholipid antibodies activates endothelial cells, whose dysfunction also plays an important role in the pathogenesis of thrombosis in BCR-ABL negative myeloproliferative neoplasia.
Aims
To evalute the antiphospholipid antibodies in relationship P Selectin Glycoprotein Ligand 1 (PSGL1) polymorphism on the development of thrombosis with other risk factors in patients with MPN.
Methods
A total of 105 MPN patients were included in this retrospective study. 58 of the MPN patients were diagnosed with essential thrombocythemia (ET), 41 with polycythemia vera (PV), 6 with myelofibrosis (MF). Clinical data about the development of thrombosis was collected. PSGL1 polymorphisms was determined from peripheral blood samples using PCR method. In electrophoresis the size of A allele was 558 bp, B allele – 528 bp. Data analysis was performed using “IBM SPSS Statistics 23”. There were two different selective and one confirmatory test for the LA determination. The detection of antibodies against β2-glycoprotein-1 (β2GP1) was performed using a chemiluminescent method. The detection of antibodies against cardiolipin (aCL) was performed by ELISA using commercial Aeskulisa Cardiolipin-GM (AESKU.DIAGNOSTICS, Germany).The interdependence of qualitative attributes was evaluated by the criterion of the chi square (χ2), and the Stjudent t-test or the Mann-Whitney U test was used to compare the quantitative characteristics. The data was statistically reliable when P<0.05.
Results
Arterial thrombotic complications were present in 38 (42.2%) of those with MPN. These patients were diagnosed with transient ischaemic attack (TIA), ischaemic stroke or myocardial infarction. aPL together with PSGL1 polymorphism were significant more frequently found in arterial thrombosis MPN patients compared with MPN patients who didn't experienced thrombosis (21.1% and 5.8%; p< 0.029).
Conclusion
Myeloproliferative neoplasm´s patients with antiphospholipid antibodies and PSGL1 polymorphism may have the increased risk of thrombosis development.
Keyword(s): Thrombosis